No internet connection — showing the saved version of the page.

Innate Pharma

FREUR
← to the screener

Innate Pharma (PA:IPH) — Biotechnology: Biological Products (No Diagnostic Substances). Number of exchanges where the company shares trade: 3. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
innate-pharma.com
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Headquarters
MARSEILLE, France
Management
Jonathan E. Dickinson
Employees
120
Founded
1999
Shares outstanding
111.7 M
Free float
70.45 M
Market cap
146.33 M EUR
Insiders
17.46%
Institutions
10.86%
Industry (SIC)
Biological Products, (No Diagnostic Substances)
Legal form
K65D
ISIN
FR0010331421
LEI
9695002Y8420ZB8HJE29
P/E
loss
FCF
−52.9 M EUR
Debt
?
Earnings and FCF — for the 12 months to 31.12.2025 (the company's latest report).
Description

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
PA Euronext ParisIPH primaryEUR1.272 -2.30%common stock
LSE London Stock Exchange0EVI IOBEUR1.304 +2.27%common stock
US USA StocksIPHYF OTCUSD1.5092 -8.53%common stock

Price for 3 months

PA:IPH · EUR
up day down dayHover / tap a day — open, close, high and low prices

News this week

Press releases from the company's investor website, updated daily. Links lead to the company's website. Headlines are in the original language, as on the company website.

Top holders

HolderStakeSharesReport date
ETF Series Solutions-Ran…0.08%72 6952025-02-28
Lion Point Capital, LP0.07%81 1512026-06-30
Morgan Stanley0.04%43 5242026-06-30
Smartharvest Portfolios,…0.02%23 7502026-06-30
Dimensional ETF Trust-Di…0.02%23 2772026-01-31
Xtx Topco Ltd0.01%15 1302026-06-30
Citadel Advisors Llc0.01%12 4412026-06-30
Jane Street Group, LLC0.01%10 3102026-06-30
Rhumbline Advisers0%4 7192026-06-30
UBS Group AG0%1 3632026-06-30
Farther Finance Advisors…0%212026-06-30
Gamma Investing LLC0%92026-06-30